Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.
Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.
Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.